Psoriasis Clinical Trial

To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.

View Full Description

Full Description

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to determine the effect of SCD-044 in subjects with moderate to severe plaque psoriasis.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Males and non-pregnant non-lactating females with a diagnosis of predominantly plaque psoriasis for ≥ 6 months as determined by subject interview and confirmation of diagnosis through physical examination by Investigator.
Aged at least 18 years.
Subjects with no history of active TB or symptoms of TB

Exclusion Criteria:

Subjects with non-plaque forms of psoriasis-like erythrodermic psoriasis, pustular psoriasis, medication-induced, or medication exacerbated psoriasis or new-onset guttate psoriasis.
Subjects who have anticipated the requirement of topical therapy, phototherapy, or systemic therapy for psoriasis during the trial.
Subjects with history or presence of uveitis

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

240

Study ID:

NCT04566666

Recruitment Status:

Recruiting

Sponsor:

Sun Pharmaceutical Industries Limited

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 24 Locations for this study

See Locations Near You

Site # 21
Yuma Arizona, 85364, United States
Site # 12
Encino California, 91436, United States
Site # 13
Los Angeles California, 90017, United States
Site # 17
North Hollywood California, 91606, United States
Site # 10
Sherman Oaks California, 91403, United States
Site # 15
Castle Rock Colorado, 80109, United States
Site # 30
DeLand Florida, 32720, United States
Site # 14
Delray Beach Florida, 33484, United States
Site # 06
Fort Lauderdale Florida, 33308, United States
Site # 19
Hialeah Gardens Florida, 33016, United States
Site # 09
Hialeah Florida, 33012, United States
Site # 26
Miami Florida, 33145, United States
Site # 31
Miami Florida, 33173, United States
Site # 04
Miami Florida, 33175, United States
Site # 05
Miramar Florida, 33027, United States
Sites # 27
Tampa Florida, 33670, United States
Site # 29
College Park Georgia, 30349, United States
Site # 08
Indianapolis Indiana, 46077, United States
Site # 08
West Lafayette Indiana, 47906, United States
Site # 07
Troy Michigan, 48084, United States
Site # 03
Dallas Texas, 75234, United States
Site # 18
Springville Utah, 84663, United States
Site # 16
Arlington Virginia, 22209, United States
Site # 22
La libertad , CP 01, El Salvador
Site # 23
San Salvador , CP 01, El Salvador
Site # 24
San Salvador , CP 01, El Salvador

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

240

Study ID:

NCT04566666

Recruitment Status:

Recruiting

Sponsor:


Sun Pharmaceutical Industries Limited

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.